Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2002

View Archived Issues

Phase III data demonstrate utility of MS-325 for enhancing MRA of vascular occlusive disease

Novel class of anti-HIV agents under evaluation at Rega Institute

Viramidine as an effective and safe liver-targeting ribavirin prodrug

SOD mimetic exerts potent anti-HIV activity and inhibits astrocyte apoptosis

Nucleoside inhibitors of HIV replication presented in Prague by U.S. university researchers

Potent analgesic effect demonstrated for duloxetine in an animal model of persistent pain

Greater global improvement in lipoprotein profiles obtained on new lipid-modifying combination

Cell death pathways activated by BMS-247550 in refractory ovarian cancer cells

Cellegy updates 2001 progress and outlook for 2002

Japanese filing made for sevelamer

ISTA updates clinical progress of Vitrase

Genaera highlights key clinical achievements of 2001

First European country approves Elidel for atopic dermatitis

WX-UK1 safe and well tolerated in phase Ia trial

Biovail acquires rights to Teveten in U.S.

Betaferon therapy shows sustained benefits and tolerability over 12 years

Comparative study of Thymoglobulin and Simulect in kidney transplant rejection closed early

Celgene develops new class of SERM with potential as both antiosteoporotic and anticancer agents

Avidex breakthrough in monoclonal T-cell receptor technology in cancer

Oxford GlycoSciences progress report

New antibacterial compounds reported by Aventis

Lilly describes new series of factor Xa inhibitors

Bristol-Myers Squibb presents new compounds for the treatment of thrombosis

FSH receptor agonists for in vitro fertilization patented by Affymax

Novel contraceptives identified by scientists at Affymax

PARP inhibitors and their uses presented by Ono

Fidia's new coumarin derivatives claimed for the treatment of vasculopathies, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...